Shots:

• Pfenex to receive R&D funding along with $2.6M up to $18M as development- regulatory & commercial milestones and royalties on WW sales of products. Arcellx to get access to Pfenex expression technology platform to advance sparX proteins- activating- silencing & reprograming antigen- receptor complex T-cell based therapies
• Arcellx’s first sparX protein has completed its process development program leading to the initiation of the second sparX program- both focusing on hematologic malignancies
• The Pfenex expression technology platform is protein expression technology based on Pseudomonas fluorescens used to develop therapeutically equivalent vaccines- biologics and biosimilars which includes CRM197- PF708- PF743 & PF745

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Pfenex